title: A young woman presenting with psychotic and mood symptoms from anti-N-methyl-D-aspartate receptor (NMDA-R) encephalitis: an emerging diagnosis.
abstract: Anti-N-methyl-D-aspartate receptor (NMDA-R) encephalitis, first characterized in 2005, is a neurological disease with prominent psychiatric features that frequently involves the consultation of psychiatrists. Since its discovery, the rate of diagnosis of new cases has increased rapidly and several epidemiological studies now confirm that NMDA-R encephalitis may be as common as many other prominent infectious etiologies of encephalitis. We describe a case of a young woman presenting initially with psychotic and mood symptoms who was found to have anti-NMDA-R encephalitis. We further provide details of her treatment and prolonged recovery process after hospital discharge with a review of the literature and discussion of the epidemiology, symptomology, diagnosis, and management of both the neurologic and psychiatric manifestations of this condition. Last, we contextualize the importance of anti-NMDA-R encephalitis for psychiatrists, highlighting the role for psychiatrists in establishing the initial diagnosis as well as in providing ongoing psychiatric care.
authors.forename: Neal
authors.initials: N
authors.lastname: Yuan
authors.forename: Anna
authors.initials: A
authors.lastname: Glezer
mesh_terms: D000328:Adult; D000341:Affective Disorders, Psychotic / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D060426:Anti-N-Methyl-D-Aspartate Receptor Encephalitis / Q000150:complications* / Q000175:diagnosis* / Q000628:therapy; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D003987:Dibenzothiazepines / Q000627:therapeutic use; D004569:Electroencephalography / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008140:Lorazepam / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D010956:Plasmapheresis / Q000379:methods; D000069348:Quetiapine Fumarate; D000069283:Rituximab; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000927:Anticonvulsants; D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D007155:Immunologic Factors; D000069348:Quetiapine Fumarate; D000069283:Rituximab; D010672:Phenytoin; D006220:Haloperidol; D008140:Lorazepam